These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 6138950

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects.
    Heikkila RE, Cabbat FS, Manzino L.
    Res Commun Chem Pathol Pharmacol; 1981 Dec; 34(3):409-21. PubMed ID: 7323442
    [Abstract] [Full Text] [Related]

  • 7. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
    Clements-Jewery S, Robson PA.
    Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
    [No Abstract] [Full Text] [Related]

  • 8. Dopamine receptor: from synaptic membranes to solubilization.
    Laduron P.
    Adv Biochem Psychopharmacol; 1980 Dec; 24():81-7. PubMed ID: 6105808
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA, Marsh CL.
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR, Molinoff PB.
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    Nakajima T, Iwata K.
    Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
    Bacopoulos NG.
    J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.